Cover
Vol. 2 No. 2 (2024)

Published: August 31, 2024

Pages: 1-7

Original Article

Design, Molecular Docking and ADME Study of New GABA Derivatives

Zaid Firas Adnan 1 SaifAli Abaid Rafal Majid Kareem Reyam Firas Muneer Tiba M Hameed
1Department of Pharmacutical Cemistry, College of pharmacy, Al-Nahrain University, Baghdad, Iraq
History
  • Received: June 30, 2024
  • Available Online: August 31, 2024

Abstract

Gamma-aminobutyric acid (GABA) plays a pivotal role in neuronal regulation within the Brain. This study aims to explore potential interactions between synthesized GABA derivatives and GATI through molecular docking simulations. Initially, GABA's historical significance and Therapeutic applications are outlined. The mechanism of action of GABAergic drugs and the role of GATI are elucidated. Subsequently, using ADME procedures and molecular docking protocols, the Physicochemical properties of synthesized compounds and their binding affinities to GATI are Investigated. Results reveal high gastrointestinal absorption and varying blood-brain barrier Permeability among the compounds. Docking studies show promising interactions, with compound G8 exhibiting notable affinity attributed possibly to hydrogen bond formations. This research offers Insights into potential drug development targeting GATI for modulating GABAergic signaling.

Keywords

References

  1. McGeer et al., 1983
  2. Gunne et al., 1984; Butterworth et al., 1983
  3. Aoyagi et al., 1990
  4. Bakay and Harris, 1981
  5. Nishino et al., 1988
  6. Bergmann KJ. Progabide: A new GABA-mimetic agent in clinical use. Clin Neuropharmacol. 1985;8:13–26.
  7. Grant SM, Heel RC. Vigabatrin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs. 1991;41:889–926.
  8. Schachter SC. A review of the antiepileptic drug tiagabine. Clin Neuropharmacol. 1999;22:312–7.
  9. Löscher W. Single-target versus multi-target drugs versus combinations of drugs with multiple targets: Preclinical and clinical evidence for the treatment or prevention of epilepsy. Front Pharmacol. 2021;12:730257.
  10. Campo-Soria, C., Chang, Y., & Weiss, D. S. (2006).
  11. https://doi.org/10.2174/1568007033482788
  12. https://doi.org/10.2174/1568007033482788
  13. https://doi.org/10.2174/156802606778249801
  14. Toth et al., 1983
  15. Guay DRP. Pregabalin in neuropathic pain: A more "pharmaceutically elegant" gabapentin? Am J Geriatr Pharmacother. 2005;3:274–287. https://doi.org/10.1016/j.amjopharm.2005.12.008
  16. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: The calcium channel a2-8 (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73:137–150. https://doi.org/10.1016/j.eplepsyres.2006.09.008.
  17. Dworkin RH, Kirkpatrick P. Pregabalin. Nat Rev Drug Discov. 2005;4:455–456. https://doi.org/10.1038/nrd1756.
  18. Gajraj NM. Pregabalin: Its pharmacology and use in pain management. Anesth Analg. 2007;105:1805–1815. https://doi.org/10.1213/01.ane.0000287643.13410.5e.